Get started

Buy-sell-indicator

PTON Peloton Potential Buyout Interest from Amazon or NikeIf you haven`t bought the dip on PTON, before the rally: Now Peloton Interactive PTON remains a compelling bullish candidate in 2025, supported not only by strategic buyout interest from major players like Amazon and Nike but also by significant unusual options activity signaling strong investor conviction in a near-term upside move. These factors combined create a powerful catalyst for a potential stock rally. 1. Confirmed Buyout Interest from Amazon and Nike Since 2022, credible reports have indicated that Amazon and Nike are exploring acquisition opportunities for Peloton, recognizing its value as a leading connected fitness platform with over 2 million subscribers. Amazon’s interest fits its broader health and smart home ambitions, while Nike sees Peloton as a strategic extension of its digital fitness ecosystem. Such buyout interest implies a potential premium valuation, which could trigger a sharp upward re-rating of Peloton’s shares if a deal materializes or even if speculation intensifies. 2. Massive Unusual Call Option Activity for July 18, 2025 Expiry A mystery trader recently purchased over 80,000 call options on Peloton with a $7 strike price expiring July 18, 2025, representing a $3.1 million bet on a price rise within the next few months. On May 20, 2025, over 90,000 contracts of the $7 strike call expiring July 18, 2025 traded, equating to roughly 9 million underlying shares—well above Peloton’s average daily volume. This unusually high call volume signals strong bullish sentiment and possible insider or institutional anticipation of a positive event, such as a buyout announcement or operational turnaround. 3. Strategic Fit and Synergies for Acquirers Peloton’s subscription-based connected fitness platform offers Amazon and Nike a valuable recurring revenue stream and engaged user base. Amazon could integrate Peloton’s offerings into its ecosystem of devices, health services, and e-commerce, while Nike could leverage Peloton’s content and hardware to deepen its digital fitness presence. The potential for cross-selling, brand synergy, and data monetization enhances Peloton’s attractiveness as an acquisition target. 4. Attractive Valuation and Growth Potential Peloton’s market cap has contracted significantly, making it an affordable target for large corporations with strategic interests in health and fitness. Recent product launches, cost-cutting measures, and renewed marketing efforts aim to stabilize and grow Peloton’s subscriber base and revenue. The connected fitness market continues to expand, driven by consumer demand for at-home and hybrid workout solutions. 5. Technical and Sentiment Indicators The stock has shown signs of stabilizing after recent volatility, with support forming near $6–$6.50. The surge in call options activity, especially at strikes above current prices, suggests growing investor confidence in a near-term breakout. Historical patterns show Peloton’s stock reacts strongly to buyout rumors and unusual options volume, often resulting in rapid price appreciation. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:PTONLong
by TopgOptions
1
SNAP Upside PotentialIf you haven`t bought SNAP before the previous earnings: SNAP Key Fundamental Strengths in Q1 2025: Metric Q1 2025 Result Year-over-Year Change Revenue $1.36 billion +14% Daily Active Users (DAU) 460 million +9% Monthly Active Users (MAU) 900 million+ Net Loss $140 million -54% (improved) Adjusted EBITDA $108 million +137% Operating Cash Flow $152 million +72% Free Cash Flow $114 million +202% SNAP strong fundamental performance in Q1 2025, marked by accelerating revenue growth, expanding user engagement, sharply improving profitability, and robust cash flow generation, sets a solid foundation for a potential stock rally this year. The company’s innovation in AR, diversified revenue streams, and healthy balance sheet further support a bullish outlook. Investors focusing on fundamentals can view Snap as a growth stock with improving financial health and significant upside potential in 2025. My price target is $14. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:SNAPLong
by TopgOptions
Why Recursion Pharmaceuticals RXRX Could Be the NVDA of BiotechRecursion Pharmaceuticals RXRX is rapidly emerging as a transformative force in drug discovery, leveraging cutting-edge artificial intelligence and automation to industrialize and accelerate the development of new medicines. Here’s why RXRX could be the next NVIDIA (NVDA) of biotechnology and why its stock could soar by year-end: 1. AI-Powered Drug Discovery Platform with Unmatched Scale Recursion integrates AI, machine learning, automation, and advanced data science to decode biology and chemistry, dramatically reducing the time and cost of drug discovery. The company’s proprietary BioHive-2 supercomputer, built with NVIDIA’s DGX H100 systems, is the most powerful AI computing system wholly owned by any biopharma company, enabling Recursion to process biological data at unprecedented speeds. By reducing the number of compounds needed for clinical candidates from thousands to just 136–200 and shrinking development timelines to under a year, RXRX is fundamentally changing the economics of pharmaceutical R&D. 2. Strategic Partnerships and Industry Validation RXRX has forged high-profile partnerships with pharmaceutical giants such as Bayer, Roche/Genentech, Takeda, and Sanofi, validating its platform and unlocking milestone payments that could exceed $20 billion over time. The company’s collaboration with AI biotech Exscientia in a $700 million deal further cements its leadership in the AI-driven drug discovery space, creating a pipeline of 10 clinical and preclinical programs with hundreds of millions in potential milestones. NVIDIA itself holds over 7.7 million shares of RXRX, making it one of NVIDIA’s largest biotech investments and a strong endorsement of Recursion’s technology and long-term vision. 3. Explosive Revenue Growth and Strong Cash Position Analysts forecast Recursion’s revenue to grow at a 65% CAGR from $58.8 million in 2024 to $263 million by 2027, far outpacing the broader biotech sector. The company ended 2024 with over $600 million in cash, providing a solid runway for continued investment in R&D, platform expansion, and clinical trials. Wall Street analysts expect more than 50% upside in RXRX stock over the next 12–24 months, with multiple clinical milestones and partnership announcements as near-term catalysts. 4. Disruptive Vision: The “Virtual Cell” and Beyond RXRX is building toward a “virtual cell,” where AI models can simulate biological processes with such accuracy that wet lab experiments shift from data generation to validating computational predictions. This approach could dramatically improve drug development success rates, addressing the industry’s notorious 95% failure rate and positioning Recursion as the go-to platform for next-generation drug discovery. 5. Market Sentiment and Institutional Support RXRX has caught the attention of growth investors and major funds, including Cathie Wood’s ARK Invest, further boosting its profile and liquidity. Recent stock surges and high trading volumes reflect growing investor confidence in Recursion’s disruptive potential and the broader AI-in-biotech trend.
NASDAQ:RXRXLong
by TopgOptions
8
MRK Merck On the Verge of a Breakout? Unusual Calls !!Merck (MRK) is setting up for what could be a high-probability breakout. The stock has been in a falling wedge pattern for several months — a classic technical formation that often precedes sharp upside moves. Price action has now compressed to the end of the wedge, and we may be on the brink of a bullish resolution. 🔍 Technical Setup Falling Wedge Pattern nearing completion Price currently hovering near long-term support ($78.25) Strong bullish divergence forming on momentum indicators (RSI/MACD) The falling wedge is typically a reversal pattern, and given how deep MRK has pulled back from its highs ($134+), the risk/reward here looks compelling. 🔥 Options Flow Today’s options market added fuel to the fire: 48,000 call contracts traded expiring this Friday This sudden surge in short-dated call buying signals aggressive positioning for an imminent move This kind of volume is not retail-driven — it points to potential institutional interest 💡 The Bullish Case With the technical breakout structure in place and strong confirmation from options flow, the case for a bullish reversal is growing. If MRK can close above wedge resistance with volume, it opens the door to a quick move toward $85+, possibly even higher in the coming weeks. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:MRKLong
by TopgOptions
CRM Salesforce Options Ahead of EarningsIf you haven`t bought CRM before this rally: nor sold this top: Now analyzing the options chain and the chart patterns of CRM Salesforce prior to the earnings report this week, I would consider purchasing the 250usd strike price Puts with an expiration date of 2025-6-20, for a premium of approximately $5.15. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:CRMShort
by TopgOptions
LUMN Lumen Technologies Options Ahead of EarningsAnalyzing the options chain and the chart patterns of LUMN Lumen Technologies prior to the earnings report this week, I would consider purchasing the 3.50usd strike price Calls with an expiration date of 2025-5-30, for a premium of approximately $0.41. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:LUMNLong
by TopgOptions
AMZN Amazon Options Ahead of EarningsIf you haven`t bought AMZN before the previous rally: Now analyzing the options chain and the chart patterns of AMZN Amazon prior to the earnings report this week, I would consider purchasing the 210usd strike price Calls with an expiration date of 2025-6-20, for a premium of approximately $3.75. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:AMZNLong
by TopgOptions
NVDA NVIDIA Price Target by Year-EndNVIDIA Corporation (NVDA) remains a dominant force in the AI and semiconductor markets, with its forward price-to-earnings (P/E) ratio currently at 19.37—a reasonable valuation considering its growth trajectory and market position. NVIDIA’s leadership in the AI sector, particularly through its cutting-edge GPUs, has driven strong demand from data centers, cloud providers, and AI developers. The company’s recent product launches, including the Hopper and Blackwell architectures, have further solidified its competitive edge. Despite recent market volatility, NVIDIA's consistent revenue growth and expanding profit margins support the bullish case. The current P/E of 19.37 reflects a balanced risk-reward profile, suggesting that the stock is not overvalued despite its impressive performance. A price target of $145 by year-end reflects approximately 15% upside from current levels, driven by sustained AI demand and growing market penetration. Investors should watch for quarterly earnings reports and updates on AI chip demand, as these will likely act as key catalysts for upward momentum.
NASDAQ:NVDALong
by TopgOptions
QQQ Nasdaq 100 Year-End Price Target and Technical Rebound SetupIf you haven`t bought the previous oversold area on QQQ: Now the Nasdaq-100 ETF (QQQ), which tracks the performance of the largest non-financial companies in the Nasdaq, has recently entered oversold territory, suggesting that a technical rebound may be imminent. Similar to the Russell 2000, QQQ has experienced significant selling pressure, driving key technical indicators into oversold zones and creating favorable conditions for a bounce. The Relative Strength Index (RSI) has dropped below 30, a level that typically signals oversold conditions and the potential for a reversal. Additionally, QQQ is trading near key support levels, with a large portion of its components underperforming their 50-day and 200-day moving averages — a classic setup for a mean reversion rally. From a historical perspective, QQQ has shown a tendency to rebound strongly after similar oversold conditions, particularly when macroeconomic factors stabilize and buying pressure returns. Given the current technical setup, my price target for QQQ is $550 by the end of the year. This represents a recovery of approximately 8-10% from current levels, aligning with previous post-oversold rallies in the index. While downside risks remain — including potential volatility around Federal Reserve policy and broader economic data — the technical backdrop suggests that QQQ is well-positioned for a recovery in the coming months.
NASDAQ:QQQLong
by TopgOptions
HPE Hewlett Packard Enterprise Company Options Ahead of EarningsIf you haven`t bought HPE before the previous earnings: Noe analyzing the options chain and the chart patterns of HPE Hewlett Packard Enterprise Company prior to the earnings report this week, I would consider purchasing the 20usd strike price Calls with an expiration date of 2025-3-21, for a premium of approximately $0.52. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
NYSE:HPELong
by TopgOptions